Skip to search formSkip to main contentSkip to account menu

trabectedin

A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the… 
National Institutes of Health

Related topics

Related topics

9 relations
Alkylating Activity [MoA]NCIt Antineoplastic Agent Terminologytrabectedin 1 MG Injection [Yondelis]

Broader (3)

Antineoplastic Agents, AlkylatingDioxolesTetrahydroisoquinolines

Narrower (3)

Ecteinascidin 743NSC 684766Yondelis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced…
Background Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding… 
2015
2015
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
Purpose Trabectedin induces synthetic lethality in tumor cells carrying defects in homologous recombinant DNA repair. We… 
2014
2014
Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
BACKGROUND Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal… 
Highly Cited
2013
Highly Cited
2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
Background:This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and… 
Review
2011
Review
2011
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
PurposeThis analysis provides a cross-study evaluation of the cardiac safety of trabectedin.MethodsDrug-related cardiac adverse… 
Review
2009
Review
2009
Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature
Abstract The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma… 
Review
2008
Review
2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
BACKGROUND Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease… 
2008
2008
Trabectedin and its potential in the treatment of soft tissue sarcoma
Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair… 
Review
2008
Review
2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
Background: Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease… 
2005
2005
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
Trabectedin (YondelisTM, formerly ET-743) is an anti-cancer drug currently undergoing phase II development. Despite extensive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)